Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Exiqon


Illumina this week released pricing details for the whole-human-genome microarray products that the company announced in January (See BAN 1/21/2004). The company said the product line will be widely available in the mid-year time frame. The Sentrix Human WG-6 BeadChip, with probes to query approximately 48,000 transcripts on each of the six whole-genome assay areas on the chips, will be priced at $960 per BeadChip. The company’s Sentrix Human RS-8 will contain probe sequences to query eight samples, each sample area containing probes to 24,000 genes derived from the March 2004 edition of the RefSeq database. The RefSeq microarray will be priced at $800 per BeadChip. The pricing is set, but the company will offer buyer incentives and priority access to the Sentrix BeadChips and related systems. The company has identified and begun working with a set of undisclosed beta customers testing the product.

Exiqon this week launched the ProbeLibrary product series for gene expression analysis using real time PCR. ProbeLibrary kits are based on new chemistries for real-time PCR where one kit constituting 90 detection probes allows for quantification of over 35,000 human or mouse genes. The product includes new assay design software, available at The product line has 99.9 percent coverage of the 1,000 most cited transcripts from RefSeq. Some 90 percent of the transcripts are tar-geted at exon-exon splice junctions, with 40 percent of all mRNA splice junctions targeted. Most transcripts are targeted by multiple probes.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.